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We have previously reported rare variants in Src homology 2 (SH2) B adaptor protein 1 (SH2B1) in
individuals with obesity, insulin resistance and maladaptive behaviour. Here, we identify four
additional SH2B1 variantsby sequencing500 individualswith severeearly-onsetobesity. SH2B1has
four alternatively spliced isoforms. One variant (T546A) lies within the N-terminal region common
to all isoforms. As shown for past variants in this region, T546A impairs SH2B1 enhancement of
nerve growth factor (NGF)-induced neurite outgrowth and the individual with the T546A variant
exhibits mild developmental delay. The other three variants (A663V, V695M and A723V) lie in the
C-terminal tail of SH2B1. SH2B1 variant carriers were hyperinsulinemic but did not exhibit the
behavioural phenotype observed in individuals with SH2B1 variants that disrupt all isoforms. In in
vitro assays, SH2B1, like SH2B1, enhances insulin- and leptin-induced IRS2 phosphorylation and
growth hormone (GH)-induced cell motility. None of the variants affect SH2B1 enhancement of
insulin- and leptin-induced IRS2 phosphorylation. However, T546A, A663V and A723V all impair
the ability of SH2B1 to enhance GH-induced cell motility. In contrast to SH2B1, SH2B1 does not
enhance NGF-induced neurite outgrowth. These studies suggest that genetic variants that disrupt
isoforms other than SH2B1may be functionally significant. Further studies are needed to under-
standthemechanismbywhich the individual isoforms regulateenergyhomeostasis andbehaviour.
Src homology 2 (SH2) B adaptor protein 1 (SH2B1) isamember of a family of scaffold proteins implicated in
signaling downstream of a variety of receptor tyrosine ki-
nases and cytokine receptors that bind to JAKs. These
include receptors for leptin, insulin, growth hormone
(GH), IGF-1, nerve growth factor (NGF), and brain-de-
rived neurotrophic factor (BDNF) (reviewed in (1)). In
mice, targeted deletion of Sh2b1 results in marked leptin
resistance, increased food intake, severe obesity and insu-
lin resistance.An intermediate obesity phenotype is seen in
heterozygous nullmice fed a high fat diet (2, 3), suggesting
that the obesity phenotype is dosage-dependent.
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Given the largenumberof receptor tyrosinekinases and
cytokine receptor/JAK complexes that bind to SH2B1 (1),
dissecting the molecular mechanisms by which SH2B1
regulates energy balance and glucose homeostasis has
proved challenging. SH2B1 is alternatively spliced to yield
four isoforms (,,,) that vary in length from671 to756
amino acids. All isoforms share a phenylalanine (Phe) zip-
per dimerization domain, nuclear localization sequence
(NLS), nuclear export sequence (NES), Pleckstrin homol-
ogy (PH) domain and SH2 domain but exhibit unique
C-termini that vary in length from 40 (SH2B1) to 125
(SH2B1) amino acids (Figure 1) (4). The human SH2B1
isoforms have distinct expression patterns. While the 
and  isoforms are widely expressed, the  and  isoforms
are restricted to brain regions (5). Although very little is
known about the physiological relevance of the different
SH2B1 isoforms, neuron-specific restoration of the beta
isoform in Sh2b1 null mice rescues the obese phenotype
(6).
We previously reported rare genetic variants in SH2B1
(P90H, T175N, P322S, F344Lfs*20) that are located in
the N-terminal 631 amino acids shared by all four iso-
forms (1–631 region). Individuals carrying these variants
exhibit severe early-onset obesity and insulin resistance,
and a neurobehavioural phenotype characterized by de-
layed speech and language development, andmaladaptive
behavior (5). These variants disrupted SH2B1 cellular
function in in vitro assays that measured GH-induced cell
motility and NGF-induced neurite outgrowth. An addi-
tional SH2B1 variant (g.9483C/T), which affects only the
beta (T656I) and gamma (P674S) isoforms, was also re-
cently identified in obese subjects (7). This variant had no
functional effect in the one assay tested (SH2B1 enhance-
ment of leptin stimulation of STAT3 activity).
Here we describe four additional SH2B1 variants iden-
tified by sequencing a further 500unrelated severely obese
individuals from the Genetics of Obesity Study (GOOS)
cohort. We performed a series of functional studies of
these new variants and those previously identified by us
(P90H, T175N, P322S, F344Lfs*20) within the context
of SH2B1. There is evidence to support not only the role
of rare variants in SH2B1 in severe obesity but also of
common variants with a broader role in the regulation of
body mass index (BMI). As such, we also studied a com-
mon coding variant (rs7498665; A484T) that has been
strongly associated with BMI in genome wide association
studies (8, 9).
Materials and Methods
SH2B1 variant analysis
500 individuals with severe early-onset obesity (defined as a
BMI sds 3; onset 10 years) were randomly selected from the
Genetics of Obesity Study (GOOS) cohort study. Primers were
designed to cover the coding sequence (NM015503) and splice
junctions of SH2B1. Variant screening was performed using
PCR, followed by direct sequencing using BigDye terminator
chemistry (AppliedBiosystems,UK)andanalysis onanABI3730
automated sequencer (Applied Biosystems, UK).
Methods for functional studies are similar to those described
previously (5) and are in the Supplement.
Results
Identification of novel SH2B1 variants in severely
obese individuals
We previously identified four variants in SH2B1
(P90H, T175N, P322S,F344Lfs*20) in individuals with
Figure 1. Identification of novel variants in SH2B1 A) Schematic showing the location of variants identified in SH2B1 identified in individuals with
severe obesity. The novel variants identified in this study are shown in red. Variants reported previously and the common SNP (A484T) are shown
in black. DD  dimerization domain, PH  Pleckstrin homology domain, SH2  SH2 domain. B) Sequence traces of the novel variants in this study.
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severe early-onset obesity from the Genetics of Obesity
(GOOS) cohort (5). In the present study, we sequenced
SH2B1 in 500 additional individuals from this cohort. In
addition to another individual carrying the T175N vari-
ant, we found three novel heterozygous variants in unre-
lated severely obese individuals: T546A (n  1), A663V
(n 14) andA723V (n 1) (Table 1).One individualwas
homozygous for V695M. As with the previously reported
variants, the T546A variant is present in all four SH2B1
isoforms. However, the three other variants (A663V,
V695M and A723V) affect the
unique C-terminal tail of SH2B1
(Figure 1). We sequenced SH2B1 in
28 available family members of se-
verely obese probands (Table 1).
A663V variants did not cosegregate
with obesity in families in a classical
Mendelian manner, suggesting that
SH2B1 variants may predispose to
obesity against a background of
other genetic and environmental fac-
tors. There were an equal number of
male and female mutation carriers
(Table 1).
Adult variant carrierswere hyper-
insulinaemic (mean fasting plasma
insulin 128  32 pmol/l; reference
range 0–60 pmol/l), but euglycae-
mic; liver function tests, lipidprofiles
and final height were in the normal
range. The individual with the
T546A variant had mild develop-
mental delay (Table 1). However, no
neurobehavioral abnormalities were
reported in individuals carrying the
A663V, V695M or A723V variants.
Differences in cellular signaling
mediated by human SH2B1
and  isoforms
We next explored the molecular
mechanisms by which these variants
might disrupt SH2B1 function. We
first studied the ability of human
SH2B1 to mediate signaling in re-
sponse to a number of ligands. As a
point of reference, we compared
these findings to those obtained us-
ing human SH2B1. Both SH2B1
and SH2B1 bind to JAK2 and en-
hance JAK2 autophosphorylation to
a similar degree (Figure 2A), consis-
tent with results of Nishi et al (10).
SH2B1 is reported to bind to IRS
proteins and promote their tyrosyl
phosphorylation in response to insu-
lin and leptin (11, 12). Like SH2B1,
Figure 2. Comparison of SH2B1 and SH2B1in vitro A) 293 cells were transfected with the
indicated constructs. Proteins in lysates were immunoprecipitated with antiflag agarose.
Immunoblotting was performed using the indicated antibodies. Results are representative of 3
experiments. B) 293LRb cells were transfected as shown, serum-starved, and then treated with
100ng/ml leptin for 5 minutes. Results are representative of 4 experiments. C) 293 cells were
transfected with the indicated constructs, serum-starved and then stimulated with 100 nM
insulin for 5min. Results are representative of 4 experiments. D) PC12 cells were transiently
transfected with the indicated constructs and treated with 25ng/ml NGF to induce neurite
outgrowth. Results show the % of GFP cells with neurites greater than twice cell body length.
Means  range, n  2 different experiments with 300 cells counted per condition per day of
NGF treatment. *P  .05 compared to GFP cells at the same time-point. Statistical significance
was assessed using two-way ANOVA and Bonferroni’s Multiple Comparisons post-test. E) Live
293T cells transiently expressing GFP-tagged human SH2B1 or SH2B1 were incubated 
leptomycin-B (LMB, 20 nM) for 4h and imaged using fluorescent confocal microscopy. Each
image is representative of 50–60 cells visualized in 2 separate experiments. Scale bar  20 m.
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SH2B1 enhances both leptin-stim-
ulated (Figure 2B) and insulin-stim-
ulated (Figure 2C) tyrosyl phosphor-
ylation of IRS2. Next, we sought to
determine whether SH2B1 is in-
volved in mediating the effects of
neurotrophins such asNGF. Surpris-
ingly,while SH2B1 enhancesNGF-
induced neurite outgrowth of PC12
cells (13), SH2B1 does not (Figure
2D). SH2B1 shuttles between the
nucleus and the cytoplasm (14).
Shuttling is thought to be necessary
for SH2B1 to enhance transcrip-
tion of NGF-responsive genes such
as uPAR, MMP3 and MMP10 (15,
16), which are implicated in neurite
outgrowth of PC12 cells (16). When
293Tcells expressing either SH2B1
or SH2B1 are treated with the nu-
clear export inhibitor, leptomycin B,
only the beta isoform is retained in
thenucleus (Figure2E).These results
indicate that SH2B1 and SH2B1
share the ability tomediate signaling
downstream of insulin, leptin and
GH.However, only the beta isoform
translocates to the nucleus and pro-
motes NGF-induced neurite
outgrowth.
Functional characterization of
variants affecting SH2B1
We next investigated the func-
tional consequences of variants
when expressed in the SH2B1 iso-
form. The distribution of SH2B1
between the plasma membrane and
the cytoplasm is not altered by any of
the variants (Figure 3A). However,
compared to SH2B1, the intensity
of SH2B1 in the plasma membrane
relative to the cytoplasm is dimin-
ished (Figure 2E, 3A). Except for the
frameshift mutant F344Lfs*20 that
lacks the SH2 domain, none of the
variants affect the ability of SH2B1
to enhance JAK2 autophosphoryla-
tion, or leptin- or insulin-induced ty-
rosyl phosphorylation of IRS2 (Fig-
ures 3B-D). As reported previously
for SH2B1 (5), the P90H and
Figure 3. Characterization of novel human variants in SH2B1 A) Live 293T cells transiently
expressing GFP-tagged rat SH2B1, human SH2B1 WT or human SH2B1 mutants were
stained with the plasma membrane marker wheat germ agglutinin Alexa Fluor 594 and imaged
by confocal microscopy. Green and red signal intensity across each cell were determined using
line scan analysis (MetaVue). The ratio of the plasma membrane: cytoplasmic signal intensity is
shown (mean SEM). *  P  .0001 by two-tailed, unpaired Student’s t test compared to the
ratio for rat SH2B1 WT, n  13–19 cells/condition. B) 293 cells were transfected with the
indicated constructs and resulting lysates subjected to immunoprecipitation with antiflag
agarose. Immunoblotting was performed using the indicated antibodies. Results are
representative of 3 experiments. C) 293LRb cells were transfected as shown, serum-starved, and
treated with 100ng/ml leptin for 5 minutes. Results are representative of 4 experiments. D) 293
cells were transfected with the indicated constructs, serum-starved and stimulated with 100 nM
insulin for 5min. Results are representative of 4 experiments. E) RAW264.7 cells (2  105 cells/
well) were transiently transfected as indicated. Migration was analyzed using a transwell
migration assay with or without GH (500 ng/ml) in the lower chamber for 18 hours. Values are
normalized to the non-hGH treated GFP-SH2B1 cells. Mean  SEM from 3–10 independent
experiments. *  P  .05 by one-tailed paired Student’s t test. F) PC12 cells transiently
expressing GFP, or GFP-tagged human SH2B1 T484, A484, or T546A, were treated with NGF
(25 ng/ml) to induce neurite outgrowth. Results show the % of GFP cells with neurites greater
than twice cell body length were counted. Means  SEM, n  3 different experiments with 300
cells counted per condition per day of NGF treatment. * P  .05 compared to GFP cells at the
same time-point. GFP-SH2B1T546A cells exhibited a statistically lower (P  .05) number of
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P332S variants reduce the ability of SH2B1 to stimulate
GH-induced cell migration. The T546A, A663V and
A723V variants also reduce GH-induced cell migration
(Figure 3E). T175N and V695M and the common SNP
(A484T)haveno impact. Finally,we tested the effect of the
variants on SH2B1 enhancement of NGF-induced neurite
outgrowth. Like wild-type SH2B1 (Figure 2D), SH2B1
A663V, V695M and A723V do not enhance NGF-in-
duced neurite outgrowth (data not shown). However, like
the previously described human variants in the 1–631 re-
gion, the T546A variant impairs the ability of SH2B1 to
enhance NGF-induced neurite outgrowth. The A484T
SNP has no effect on SH2B1 enhancement of NGF-in-
duced neurite outgrowth (Figure 3F).
Discussion
Here we describe the identification of four novel variants
in SH2B1 that are present in individuals with obesity and
insulin resistance. Some of the variants we found in se-
verely obese individuals are also found in publicly avail-
able exomes (Table 1). However, as BMI and additional
phenotypic information for individuals in these datasets
are not available, the precise contributionof these variants
to obesity remains to be established.
These findings suggest that SH2B1 contains a spectrum
of common and rare alleles which contribute to BMI and
obesity predisposition with a broad range of penetrance,
from low to more highly penetrant rare alleles. One vari-
ant, A663V, was identified in 14 severely obese individ-
uals in the GOOS cohort as well as in many publically
available exomes. In cells, A663V affected the ability of
SH2B1 to enhance cell motility in response to GH, there-
fore, it is possible that this variant may contribute to the
phenotype of variant carriers. Additional genetic studies
will be needed to determine whether this variant is signif-
icantly enriched in obese cohorts compared to controls.
The nucleotide change that causes the A663V variant in
SH2B1 also causes an amino acid change (R680C) in the
delta isoform of SH2B1. Mutation of this residue in
SH2B1 impairs the ability of SH2B1 to enhance NGF-
induced neurite outgrowth (data not shown), a finding
that requires further investigation.
We also studied the common coding SNP, A484T.
A484T did not impact upon SH2B1 or SH2B1 in the
functional assays employed here. This is consistent with a
previous study (7), which was unable to demonstrate any
functional consequence of the A484T SNP. It is possible
that this SNP affects cellular functions of SH2B1 other
than those tested or it may have subtle functional conse-
quences that cannot be detected in the cell systems and
assays we employed.
We previously showed that individuals carrying
heterozygous variants in the 1–631 region of SH2B1were
hyperphagic, with a reduced final height, elevated plasma
insulin levels that are disproportionate to the degree of
obesity, and surprisingly, maladaptive behavior (5). Con-
sistent with these findings, the individual carrying the
T546A variant had a markedly elevated fasting plasma
insulin of 123 pmol/l at age 6 years andmild developmen-
tal delay. While individuals carrying the A663V, V695M
and A723V variants were hyperinsulinaemic, none of
themwere reported to display any of the behavioral char-
acteristics reported previously. Given the small number of
individuals studied, these observations need to be repli-
cated in additional studies. We also need to determine, at
the mechanistic level, whether the behavioral phenotype
results from disruption of a specific SH2B1 isoform
(eg,SH2B1) or a function emanating from the 1–631
region shared by all 4 isoforms.
Three of the variants identified in this study are present
within the unique C-terminal tail of SH2B1 but not
SH2B1. A limited number of studies have compared the
actions of the various isoforms in vitro. All four SH2B1
isoforms enhanced mitogenesis and cell proliferation in
response to IGF-1, insulin and platelet-derived growth
factor (PDGF) stimulation (4, 17). Stable expression of
each isoform in NIH3T3 fibroblasts led to enhanced in-
sulin receptor autophosphorylation and phosphorylation
of IRS1 (17). In 3T3-L1 cells, all four isoforms enhance
insulin-stimulated glucose and amino acid transport, gly-
cogen synthesis, lipogenesis, Akt activity, and p70 S6 ki-
nase activity (18). In all of these assays, SH2B1 was as
effective as, or more effective than, SH2B1. Thus, it was
surprising to observe the inability of SH2B1 to enhance
NGF-induced neurite outgrowth. The finding that the
gamma and delta isoforms of SH2B1 resemble SH2B1 in
their ability to enhance NGF-induced neurite outgrowth
(data not shown) suggest that the uniqueC-terminal tail of
SH2B1 inhibits at least some functions mediated by the
region of SH2B1 between amino acids 1–631. In contrast
to its inability to promote NGF-induced neurite out-
growth, SH2B1, like SH2B1, was found to enhance
GH-induced macrophage motility. Exactly how SH2B1
stimulates motility is not known. However, one of the
proline-rich regionspresent inall isoformshasbeen shown
to bind Rac (23), a protein known to be involved in mo-
tility. Ligand-dependent phosphory-
lation of tyrosines within SH2B1 ap-
pears to be critical for SH2B1
neurite outgrowths at days 1–3 compared to GFP-SH2B1A484 and T484. Statistical significance
was assessed using two-way ANOVA and Bonferroni’s Multiple Comparisons post-test.
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enhancement of GH-dependent cell motility (24) suggest-
ing that these phosphorylated tyrosines may recruit crit-
ical proteins to SH2B1 complexes. SH2B1 has also been
shown to increase NGF-induced migration of PC12 cells
in a wounding assay, perhaps by a protein kinase C-de-
pendent process (25). The finding that most of the human
variants impair the ability of SH2B1 and  to enhance
motility raises the possibility that regulation of the actin
cytoskeleton and/or motility of cells is an important and
vital component of SH2B1 function that plays a critical
role in the ability of SH2B1 to regulate energy balance and
the response to insulin.
SH2B1 is among a small number of adaptor proteins
that undergo nucleocytoplasmic shuttling (14) although
its exact role within the nucleus is not yet clear. Our pre-
vious studies suggest that neurite outgrowth requires nu-
clear SH2B1 (16). Human mutations such as P90H,
T175N, P322S and F344Lfs*20 that reside in the 1–631
region of SH2B1 impair both nuclear accumulation in the
presence of LMB and enhancement of NGF-induced neu-
rite outgrowth (5). Our finding here that SH2B1 neither
accumulates in the nucleus nor enhances NGF-induced
neurite outgrowth is consistent with SH2B1 enhance-
ment of neurite outgrowth requiring nuclear SH2B1. In
contrast to neurite outgrowth, SH2B1 enhancement of
GH-induced macrophage motility does not require its nu-
clear localization (26), a finding consistent with our ob-
servation here that SH2B1 retains the ability to enhance
macrophage motility despite its inability to enter the nu-
cleus. It is possible that the unique C-terminal tail of
SH2B1 interferes with the region of SH2B1 that is re-
quired for nuclear localization. Masking of the region
around the NLS in SH2B1 might explain why altering
amino acid 175, which lies near theNLS, impairs the abil-
ity of SH2B1 but not SH2B1 to enhance GH-induced
macrophage migration.
In summary,we have identified additional SH2B1 vari-
ants in individuals with obesity and that implicate SH2B1
isoforms besides SH2B1 as important for the regulation
of body weight. Further studies will be needed to under-
stand how the distinct C-terminal tails of the alpha, beta,
gamma and delta isoforms influence SH2B1 function and
their precise roles in vivo.
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